New research indicates that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who stop conventional diet and exercise regimens.
Published data in a leading medical journal points out that while obese individuals frequently drop about a fifth of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals using these treatments must be aware of the potential of quick rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to starting mass in about a year and a half.
Comparing Treatments
The research, which reviewed dozens of studies involving over 9,000 of participants, compared the effects of these new drugs with other pills.
Scientists note that individuals who shed pounds through lifestyle changes alone generally see a more gradual creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Rapid Regain
Nutrition scientists propose the mechanism of the jabs accounts for the amplified rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making excessive eating far more likely."
A Lifelong Issue?
Medical guidelines recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the treatment should be considered life-long.
This perspective is supported by pharmaceutical companies, who state that the findings "highlight the persistent nature of obesity," comparing it to managing conditions like diabetes.
Patient Testimonies
People who have stopped the medication explain a powerful resurgence of cravings.
"I experienced a trigger that goes on and I was suddenly ravenous," said a patient.
This difficulty is worsened if patients have not adopted lasting lifestyle or habit changes during therapy.
Significant Adoption
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is higher among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, researchers stress that while these medications are effective tools for weight loss, they are not a standalone fix and maintained weight loss relies on integrated lifestyle support.
